Pancreatic Cancer Research

ResearcherNational Health Research Institutes, TaiwanNo recent work listed

Li-Tzong Chen

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.

Their work

Papers
0
Trials
3 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 trial · 2019: none · 2020: none · 2021: 1 trial

Trials 3

  1. A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pa… Study chair NCT05026905↗
  2. Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers Study chair NCT03162510↗
  3. Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer Principal investigator NCT00813163↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yung-Yeh Su · 1 shared trial, 2021 · strength 0.33
  2. Shang-Hung Chen · 1 shared trial, 2021 · strength 0.33
  3. Andrew H. Ko · 1 shared trial, 2009 · strength 0.05
  4. Yulin Lin · 1 shared trial, 2009 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.